Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2015 December;70(6) > Minerva Chirurgica 2015 December;70(6):393-9



To subscribe
Submit an article
Recommend to your librarian


Cite this article as



Minerva Chirurgica 2015 December;70(6):393-9


language: English

Lung cancer screening with low dose CT: experience at Campus Bio-Medico of Rome on 1500 patients

Crucitti P., Gallo I. F., Santoro G., Mangiameli G.

Division of Thoracic Surgery, Department of General Surgery, Campus Bio‑Medico, University of Rome, Rome, Italy


AIM: The main purpose of our project was to evaluate the prevalence of lung cancer in high risk, asymptomatic individuals in addition to quantifying the rate of surgically resectable tumors, and evaluating the role of lung cancer with low dose computed tomography (LDCT) as a tool for lung cancer screening.
METHODS: Between June 2011 and March 2014, 1500 volunteers at high risk for lung cancer were enrolled in our study and underwent LDCT in our institution. The subsequent diagnostic and therapeutic steps were planned in relation to the results emerging from LDCT. To evaluate speed and type of growth, solid nodules ≤4 mm were reassessed with annual LDCT, those >4-6 mm or >6-8 mm were reassessed with LDCT in 6 or 3 months while nodules suspicious for malignancy were investigated with PET-CT or biopsy according to NCCN guidelines.
RESULTS: Non-calcified nodules were detected in 525 subjects (35% of population): among these 42% had a diameter ≤4 mm, 43% had a diameter >5 mm but <10 mm, 3% appeared as “ground glass” lesions, and 63 (12% of detected nodules) had malignant characteristics (irregular margins, retraction of the surrounding parenchyma, diameter >10 mm). Among the 63 patients who underwent PET-CT or biopsy, 25 cases resulted positive for lung cancer (1.7% of population). These patients underwent surgical treatment with histological detection of tumors in stages IA, IB or IIB.
CONCLUSION: Our study confirmed the emerging data on the use of LDCT as a screening tool for lung neoplasm in individuals at risk. Due to the LDCT low rate of specificity complementary biomarkers are required to properly define patients at risk and to reduce the number of further radiological examinations.

top of page